Form 4: Firefly Neuroscience Director Granted Equity

Firefly Neuroscience, Inc. Director Brian M. Posner was granted 49,262 deferred stock units under the company's 2024 Long-Term Incentive Plan.

Summary

• Brian M. Posner, a Director and 10% Owner of Firefly Neuroscience, Inc. (AIFF), was granted 49,262 deferred stock units (DSUs).
• The grant occurred on October 28, 2025, under the Issuer's 2024 Long-Term Incentive Plan.
• Each DSU represents a contingent right to receive one share of the Issuer's common stock.
• These DSUs will vest quarterly over a twelve (12)-month period.
• Following this transaction, Mr. Posner beneficially owns 65,929 derivative securities (DSUs).

Sentiment

Score: 6

Explanation: Slightly positive as it indicates alignment of director's interests with shareholders through equity compensation, a standard corporate governance practice.

Positives

• The grant of deferred stock units to a director aligns management's interests with those of shareholders, encouraging long-term value creation.
• Equity compensation is a standard practice to attract and retain experienced board members.

Negatives

• No negative information is presented in this routine insider transaction report.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The 49,262 deferred stock units granted to Director Brian M. Posner will vest quarterly over a twelve-month period, indicating a future increase in his direct ownership of common stock as units convert.

Management Comments

• No direct management comments or quotes are provided in this Form 4 filing.

Industry Context

Equity grants, such as Deferred Stock Units, are a common form of executive and director compensation across various industries, particularly in technology and growth-oriented sectors like neuroscience. These grants are designed to incentivize long-term performance and align the interests of key personnel with shareholder value.

Comparison to Industry Standards

• Equity compensation for directors is a standard practice across publicly traded companies, including those in the biotechnology and healthcare sectors.
• The use of Deferred Stock Units (DSUs) with a vesting schedule is a common mechanism to retain talent and ensure long-term commitment, comparable to practices at companies like Biogen Inc. or Eli Lilly and Company, which also utilize various forms of equity awards for their leadership.
• The grant size of 49,262 DSUs would typically be evaluated in the context of the company's overall compensation philosophy, market capitalization, and peer group compensation data, though specific comparative figures are not provided in this filing.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings are mentioned in this filing.

Related Party Transactions

• This filing reports an insider transaction, specifically an equity grant to a director, which is a common form of compensation and not typically classified as an adverse related party transaction.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this specific filing.
• Management: Reinforces the director's commitment and incentivizes long-term performance.

Next Steps

• The granted Deferred Stock Units will vest quarterly over the next twelve months.
• Upon vesting, these DSUs will convert into shares of Firefly Neuroscience, Inc. common stock.

Key Dates

Keywords

Firefly Neuroscience, AIFF, Brian Posner, Form 4, Insider Transaction, Deferred Stock Units, DSU, Equity Compensation, Director, Long-Term Incentive Plan